Achaogen, Inc. to Post Q4 2017 Earnings of ($0.72) Per Share, William Blair Forecasts (AKAO)
Achaogen, Inc. (NASDAQ:AKAO) – Stock analysts at William Blair lowered their Q4 2017 earnings per share (EPS) estimates for Achaogen in a report issued on Thursday. William Blair analyst Y. Xu now forecasts that the biopharmaceutical company will post earnings of ($0.72) per share for the quarter, down from their prior estimate of ($0.66). William Blair also issued estimates for Achaogen’s Q1 2018 earnings at ($0.73) EPS, Q2 2018 earnings at ($0.75) EPS, Q3 2018 earnings at ($0.70) EPS, Q4 2018 earnings at ($0.61) EPS and FY2018 earnings at ($2.78) EPS.
Several other equities research analysts have also issued reports on AKAO. Stifel Nicolaus reduced their price objective on shares of Achaogen from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, November 9th. Mizuho reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Achaogen in a research note on Thursday, September 28th. BidaskClub lowered shares of Achaogen from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 12th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Achaogen in a research note on Thursday, November 9th. Finally, Zacks Investment Research raised shares of Achaogen from a “sell” rating to a “hold” rating and set a $27.00 price objective for the company in a research note on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $25.78.
Shares of Achaogen (NASDAQ AKAO) opened at $13.01 on Monday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 6.99 and a current ratio of 6.99. Achaogen has a 52 week low of $4.67 and a 52 week high of $27.79.
Achaogen (NASDAQ:AKAO) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.13). Achaogen had a negative net margin of 593.61% and a negative return on equity of 80.44%. The company had revenue of $0.58 million for the quarter, compared to analysts’ expectations of $2.09 million. During the same quarter in the prior year, the firm earned ($0.41) earnings per share. The company’s revenue was down 96.4% on a year-over-year basis.
Institutional investors and hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. acquired a new position in shares of Achaogen during the first quarter valued at about $3,064,000. Marcus Capital LLC acquired a new position in shares of Achaogen during the second quarter valued at about $1,769,000. Bank of New York Mellon Corp raised its position in shares of Achaogen by 68.5% during the second quarter. Bank of New York Mellon Corp now owns 191,670 shares of the biopharmaceutical company’s stock valued at $4,165,000 after buying an additional 77,887 shares during the last quarter. TimesSquare Capital Management LLC raised its position in shares of Achaogen by 106.7% during the second quarter. TimesSquare Capital Management LLC now owns 1,088,300 shares of the biopharmaceutical company’s stock valued at $23,649,000 after buying an additional 561,700 shares during the last quarter. Finally, Artal Group S.A. raised its position in shares of Achaogen by 233.3% during the second quarter. Artal Group S.A. now owns 200,000 shares of the biopharmaceutical company’s stock valued at $4,346,000 after buying an additional 140,000 shares during the last quarter. 83.81% of the stock is owned by institutional investors and hedge funds.
In other Achaogen news, COO Blake Wise sold 3,576 shares of the business’s stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $15.99, for a total transaction of $57,180.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.36% of the stock is owned by insiders.
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.